4.6 Article

Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

期刊

LANCET RESPIRATORY MEDICINE
卷 9, 期 4, 页码 349-359

出版社

ELSEVIER SCI LTD
DOI: 10.1016/S2213-2600(20)30559-2

关键词

-

资金

  1. National Institute for Health Research (NIHR)
  2. UK Medical Research Council
  3. Wellcome Trust
  4. Department for International Development
  5. Bill AMP
  6. Melinda Gates Foundation
  7. EU Platform for European Preparedness Against (Re-)emerging Epidemics
  8. NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool
  9. NIHR HPRU in Respiratory Infections at Imperial College London
  10. MRC [MC_PC_19026, MR/V033441/1, MC_UU_12023/21, MC_PC_19025, MC_UU_12014/9] Funding Source: UKRI
  11. UKRI [MR/S032304/1] Funding Source: UKRI

向作者/读者索取更多资源

A prognostic model was developed and validated to predict the risk of clinical deterioration in acute COVID-19 cases. The model showed consistent discrimination, calibration, and clinical utility across different regions, demonstrating strong potential for informing decision making among hospitalized adults with COVID-19.
Background Prognostic models to predict the risk of clinical deterioration in acute COVID-19 cases are urgently required to inform clinical management decisions. Methods We developed and validated a multivariable logistic regression model for in-hospital clinical deterioration (defined as any requirement of ventilatory support or critical care, or death) among consecutively hospitalised adults with highly suspected or confirmed COVID-19 who were prospectively recruited to the International Severe Acute Respiratory and Emerging Infections Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) study across 260 hospitals in England, Scotland, and Wales. Candidate predictors that were specified a priori were considered for inclusion in the model on the basis of previous prognostic scores and emerging literature describing routinely measured biomarkers associated with COVID-19 prognosis. We used internal-external cross-validation to evaluate discrimination, calibration, and clinical utility across eight National Health Service (NHS) regions in the development cohort. We further validated the final model in held-out data from an additional NHS region (London). Findings 74 944 participants (recruited between Feb 6 and Aug 26, 2020) were included, of whom 31 924 (43.2%) of 73 948 with available outcomes met the composite clinical deterioration outcome. In internal-external cross-validation in the development cohort of 66 705 participants, the selected model (comprising 11 predictors routinely measured at the point of hospital admission) showed consistent discrimination, calibration, and clinical utility across all eight NHS regions. In held-out data from London (n=8239), the model showed a similarly consistent performance (C-statistic 0.77 [95% CI 0.76 to 0.78]; calibration-in-the-large 0.00 [-0.05 to 0.05]); calibration slope 0.96 [0.91 to 1.01]), and greater net benefit than any other reproducible prognostic model. Interpretation The 4C Deterioration model has strong potential for clinical utility and generalisability to predict clinical deterioration and inform decision making among adults hospitalised with COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据